Deal Summary – Ashbourne Pharmaceutical
| CLIENT: | Ashbourne Pharmaceuticals |
| SECTOR: | Pharmaceuticals |
| DESCRIPTION: | Provider of services and products to the UK Dispensing Doctor market |
| DEAL TYPE: | Trade sale, exit for Montagu Private Equity |
| DEAL SIZE: | Undisclosed |
| INVESTOR: | Sinclair Pharma plc |
Company background
Ashbourne Pharmaceuticals is a UK pharmaceutical sales and marketing business, which specialises in delivering co-promotional services and products to the UK Dispensing Doctor market.
Ashbourne has served the Dispensing Doctor market for some 20 years and as a result is the leading specialist provider of sales and marketing services in this market. The Ashbourne brand is well-established and this is a key factor in its success in the Dispensing Doctor market.
Deal background
Sinclair Pharma plc is an AIM-quoted, international specialty pharmaceutical company focused on the sourcing and acquisition of innovative products, registration and commercialisation of those products. Sinclair currently focuses on dermatology, oral health and ophthalmology. Sinclair has a global network of marketing partners in 60 countries. The company is also expanding its own sales and marketing capacity, with operations already present in France, Italy, Spain and Portugal. Ashbourne is an ideal platform investment for developing the UK sales presence of Sinclair Pharma plc.
Commenting on the sale, Tom Chaloner of Montagu Private Equity said: “We were impressed with the deal process managed by Alaris. In particular the hands-on support and guidance provided by Alaris to the management team which led to a successful sale outcome. We would recommend Alaris".
Dr Huw Jones, Non-Executive Chairman of Ashbourne said: "Alaris provided us with a persistent team of highly personable people with whom we enjoyed working. Their greatest strengths are their persistence and excellent negotiation skills."